Tumour localisation with a radioactively labelled reshaped human monoclonal antibody

V. Hird, M. Verhoeyen, R. A. Badley, D. Price, D. Snook, C. Kosmas, C. A. Gooden Bamias, C. Meares, J. P. Lavender, A. A. Epentos

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.

Original languageEnglish (US)
Pages (from-to)911-914
Number of pages4
JournalBritish Journal of Cancer
Issue number5
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Tumour localisation with a radioactively labelled reshaped human monoclonal antibody'. Together they form a unique fingerprint.

Cite this